J Law Med Ethics. 2022;50(S1):47-50. doi: 10.1017/jme.2022.35.
Prior to the recent introduction of generic TDF/FTC in the U.S., access to pre-exposure prophylaxis (PrEP) for HIV was greatly limited due to the downstream effects of the high cost of the medication. This article argues that despite drug copay cards and patient assistance programs, the promise of drastically reduced HIV diagnoses has never been fully realized, and more policy reforms on drug pricing are needed to make ending the HIV epidemic a reality.
在美国最近推出通用 TDF/FTC 之前，由于药物高成本的下游影响，艾滋病毒暴露前预防 (PrEP) 的可及性受到了极大限制。本文认为，尽管有药品共同支付卡和患者援助计划，但大幅降低艾滋病毒诊断率的承诺从未完全实现，需要对药品定价进行更多政策改革，才能使终结艾滋病毒流行成为现实。
